<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121822</url>
  </required_header>
  <id_info>
    <org_study_id>GRT90</org_study_id>
    <secondary_id>2009-017690-38</secondary_id>
    <secondary_id>UTN: U1111-1112-8285</secondary_id>
    <nct_id>NCT01121822</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)</brief_title>
  <official_title>Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the new formulation of the influenza vaccine for the&#xD;
      2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the&#xD;
      corresponding population and to check its compliance with the Committee for Proprietary&#xD;
      Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split&#xD;
           virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for&#xD;
           Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 in both&#xD;
           age groups&#xD;
&#xD;
        -  To describe the safety of the influenza vaccine (split virion, inactivated) NH 2010-2011&#xD;
           formulation in both age groups&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will receive a dose of vaccine on Day 0 and will be followed up for 21 days&#xD;
      post-vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of the Influenza virus vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation.</measure>
    <time_frame>21 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: To provide information concerning the safety of the Influenza virus vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation.</measure>
    <time_frame>21 days post-vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants at age 18 to 59 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants at age 60 years or older</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine (split virion, inactivated)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza virus vaccine (split virion, inactivated)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Aged 18 years or over on the day of inclusion&#xD;
&#xD;
          -  Informed consent form has been signed and dated&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures&#xD;
&#xD;
          -  For a woman of childbearing potential, use of an effective method of contraception or&#xD;
             abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after&#xD;
             vaccination&#xD;
&#xD;
          -  Entitled to national social security.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection&#xD;
             (according to investigator judgment) on the day of vaccination&#xD;
&#xD;
          -  Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and&#xD;
             octoxynol-9, or to any of the vaccine components, or history of a life-threatening&#xD;
             reaction to the vaccine used in the trial or to a vaccine containing any of the same&#xD;
             substances&#xD;
&#xD;
          -  Known pregnancy, or a positive urine pregnancy test&#xD;
&#xD;
          -  Currently breastfeeding a child&#xD;
&#xD;
          -  History of pandemic H1N1 influenza vaccination&#xD;
&#xD;
          -  History of clinically or laboratory confirmed pandemic H1N1 influenza infection&#xD;
&#xD;
          -  History of influenza vaccination within the previous 6 months (other than pandemic&#xD;
             H1N1 influenza vaccine)&#xD;
&#xD;
          -  Receipt of an adjuvanted influenza vaccine in a clinical trial within the previous 12&#xD;
             months&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency, resulting for example&#xD;
             from:&#xD;
&#xD;
               -  End-stage renal disease requiring dialysis&#xD;
&#xD;
               -  Active neoplastic disease or active hematologic malignancy&#xD;
&#xD;
               -  Receipt of immunosuppressive therapy or other immune-modifying drugs such as, but&#xD;
                  not limited to: anti-cancer chemotherapy or radiation therapy within the&#xD;
                  preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or&#xD;
                  equivalent for more than 2 consecutive weeks within the past 3 months)&#xD;
&#xD;
          -  History of seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or&#xD;
             Hepatitis C&#xD;
&#xD;
          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere&#xD;
             with assessment of the immune response&#xD;
&#xD;
          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might&#xD;
             interfere with trial conduct or completion&#xD;
&#xD;
          -  History of thrombocytopenia, contraindicating intramuscular (IM) vaccination&#xD;
&#xD;
          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,&#xD;
             contraindicating IM vaccination&#xD;
&#xD;
          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination&#xD;
&#xD;
          -  Planned receipt of any vaccine in the 3 weeks following the trial vaccination&#xD;
&#xD;
          -  Participation in another clinical trial investigating a vaccine, drug, medical device,&#xD;
             or medical procedure in the 4 weeks preceding the trial vaccination&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period&#xD;
&#xD;
          -  Deprived of freedom by an administrative or court order, or in an emergency setting,&#xD;
             or hospitalized involuntarily&#xD;
&#xD;
          -  Current alcohol abuse or drug addiction that might interfere with the ability to&#xD;
             comply with trial procedures&#xD;
&#xD;
          -  Identified as employees of the Investigator or study center, with direct involvement&#xD;
             in the proposed study or other studies under the direction of that Investigator or&#xD;
             study center, as well as family members (i.e., immediate, husband, wife and their&#xD;
             children, adopted or natural) of the employees or the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gieres</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>MONTPELLIER Cedex 5</city>
        <zip>34094</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouffach</city>
        <zip>68250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>Influenza virus</keyword>
  <keyword>Intramuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

